JeanMarie Guenot is a highly successful businesswoman that has worked for a variety of pharmaceutical and business companies. As of 2013, she is currently the CEO and President of Amphivena Therapeutics. Amphivena Therapeutics is a biotech company in San Francisco, California that specializes in treating hematological cancer with immunotherapy.
She attended the University of California and graduated with a Ph.D. in 1993. Following graduation, she worked for six years at Hoffman-Loche as a team leader and principal scientist. Guenot attended the Wharton School of the University of Pennsylvania and graduated with an MBA. Upon graduation, she began working at Atlas Venture as a business consultant. In 2003, Guenot became the Vice President of PDL BioPharma, which is a company that helps treat cancer and immune system diseases. In 2009, JeanMarie Guenot became a managing partner of Guenot, LLC. In the same year, she founded SKS Ocular LLC, a biotech company in San Diego, California. In 2013, she became the President and CEO at her current job, Amphivena Therapeutics. She resides over the development of research that specializes in treating blood cancers.
JeanMarie Guenot’s involvement at Amphivena Therapeutics is essential in treating severe blood disorders. Currently, the company plans to develop a therapy that uses the patient’s immune system to fight deadly diseases. They hope to one day have a cure for multiple myeloma and leukemia. In August 2016, the FDA approved an investigational new drug to treat acute myeloid leukemia and is now being tested in clinical trials on takeda.com.
As you can see, JeanMarie Guenot is a highly accomplished individual in the pharmaceutical field. She has dedicated her career to the research and development of medical drugs that may one day help find the cure for cancer. Under her guidance, Amphivena Therapeutics will continue to be at the forefront of medical research for many years to come.
Learn more about Jeanmarie Guenot: http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/